Business
NeuPath Health Inc. Announces $8 Million Bought Deal Offering of Units
NeuPath Health Inc. Announces $8 Million Bought Deal Offering of Units Canada N...
About this update from Neupath Health Inc.
[{"type":"text","content":"\n \n \n \n NeuPath Health Inc. Announces $8 Million Bought Deal Offering of Units\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n TORONTO, Oct. 19, 2020\n \n \n \n \n \n /NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN\n \n THE UNITED STATES\n \n ./\n \n \n \n \n TORONTO\n \n ,\n \n Oct. 19, 2020\n \n /CNW/ - NeuPath Health Inc. (TSX-V:NPTH) (formerly Klinik Health Ventures Corp.) (\"NeuPath\" or the \"Company\"),\n \n Canada's\n \n largest provider of chronic pain management services, is pleased to announce that it has entered into an agreement with Stifel GMP as co-lead underwriter and sole bookrunner and INFOR Financial Inc. as co-lead underwriter, together with a syndicate of underwriters including Haywood Securities Inc. (collectively, the \"Underwriters\"), which have agreed to purchase, on a \"bought deal\" basis 8,890,000 units (the \"Units\") of the Company at a price of\n \n $0.90\n \n per Unit, for aggregate gross proceeds of\n \n $8,001,000\n \n .  The Underwriters will also have the option, exercisable in whole or in part at any time on or up to 30 days after the closing of the offering, to purchase up to an additional 1,333,500 Units. In the event that the option is exercised in its entirety, the aggregate gross proceeds of the offering will be\n \n $9,201,150\n \n .\n \n \n Each Unit will be comprised of one common share of the Company (a \"Common Share\") and one-half of one Common Share purchase warrant (each whole Common Share purchase warrant, a \"Warrant\"). Each Warrant will be exercisable to acquire one Common Share (a \"Warrant Share\") for a period of 24 months following the closing of the Offering (the \"Closing\") at an exercise price of\n \n $1.25\n \n per Warrant Share.\n \n \n In the event that the volume weighted average trading price of the Common Shares for any twenty (20) consecutive trading days on the TSX Venture Exchange exceeds\n \n $1.75\n \n , the Company shall have the right to accelerate the expiry date of the Warrants upon not less...